🧬 BioMed Pulse · 2026-10-23 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Friday, October 23, 2026 | Edition #BPXX

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now spread to a confirmed imported case in Kenya, marking a dangerous new geographic expansion of what is already the largest Ebola outbreak ever recorded in the DRC. [1]

The overall mood is elevated concern: multiple simultaneous outbreaks remain active globally, a mystery pneumonia death at a Russian biodefense lab is under investigation, and longevity research is producing promising but early-stage regenerative findings. [2]

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) - DRC AND REGIONAL SPREAD

  • On 5 October 2026, WHO was notified of a laboratory-confirmed imported case of Bundibugyo virus disease (BVD) in Kenya, in a patient who traveled from the DRC through Uganda; the patient was hospitalized in Kenya. [1]
  • As of 25 September 2026, the DRC outbreak had expanded to two additional health zones, including Bulu in Sud Ubangi province - a new northwestern province - indicating continued geographic spread across a vast area of the country. [3]
  • As of 15 July 2026, the DRC outbreak had reached 2,124 confirmed cases and 828 deaths, making it the largest Ebola outbreak ever reported in the DRC and expanding faster than any previous Ebola outbreak. [4]
  • The outbreak originally began in Mongbwalu Health Zone, Ituri Province, and has since spread across at least 6 of 26 provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [5]
  • By 1 July 2026, Uganda had also confirmed cross-border transmission, with the DRC alone reporting 1,460 confirmed cases including 452 deaths at that date. [6]
  • The causative agent is Bundibugyo virus (BVD), a distinct Ebola virus species first identified in Uganda in 2007, with a case fatality rate in this outbreak running near 30 percent among confirmed cases. [7]
  • WHO declared this a Public Health Emergency of International Concern and the U.S. had activated enhanced airport Ebola screening at Washington-Dulles and Atlanta prior to the U.S. WHO withdrawal. [8] [9]

PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA

  • On 2 October 2026, WHO became aware through media reports of the death of an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East, Russian Federation, who died following hospitalization for severe pneumonia of unknown cause. [2]
  • The Irkutsk APRI is a biodefense research facility; the pathogen responsible for the pneumonia death has not been publicly confirmed, and WHO is seeking further information from Russian authorities. [2]
  • This event warrants close monitoring given the institutional context; no additional cases have been publicly reported at this time. [2]

MERS-CoV - SAUDI ARABIA

  • Between 1 January and 5 October 2026, Saudi Arabia reported 8 laboratory-confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), including 1 death. [10]
  • Cases were detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh (2 cases), Tabuk, and at least one additional site. [10]
  • MERS-CoV transmission remains primarily zoonotic (dromedary camels) with limited human-to-human spread; traveler vigilance is advised for the Arabian Peninsula. [10]

LISTERIA - PREPARED MEALS, ONGOING U.S. OUTBREAK

  • CDC continues to warn that illnesses are being reported despite product recalls linked to a Listeria outbreak tied to prepared meals; consumers are urged to check refrigerators and freezers for recalled products and discard them immediately.
  • Earlier updates to this outbreak noted 3 additional illnesses and 1 additional death added to the total, and the implicated product list was expanded to include more prepared foods beyond the original chicken fettuccine alfredo.

SALMONELLA - MULTIPLE ONGOING U.S. OUTBREAKS

  • A Salmonella outbreak linked to moringa leaf powder products has expanded significantly; as of 29 January 2026, 65 people across 28 states were reported sick, with additional recalls issued.
  • An extensively drug-resistant (XDR) Salmonella strain linked to moringa powder capsules has been identified, with 3 hospitalizations reported as of February 2026.
  • A separate Salmonella outbreak linked to backyard poultry sickened 34 people across 13 states as of April 2026, later updated to 150 additional cases with over a quarter in children under age 5.

DRUG-RESISTANT BACTERIA

  • A CDC report published September 2025 found a dramatic increase in dangerous drug-resistant bacteria in the United States, continuing the global trend of antimicrobial resistance expansion.

🧬 LONGEVITY & AGING

NEURONAL SENESCENCE AND EPIGENETIC REPROGRAMMING

  • A study published in Genes and Disease (July 2026) found that the transcription factor Glis1 promotes H3K18 lactylation - an epigenetic modification driven by lactate - to reduce neuronal senescence (cellular aging) following spinal cord injury, suggesting a metabolic pathway that could be targeted to protect aging neurons after injury.
  • Lactylation is a recently discovered form of protein modification where lactate - a byproduct of metabolism - chemically tags histones to change which genes are switched on or off in cells, opening a new angle on how metabolic state influences brain aging.

SENOLYTIC TARGETING FOR DISC DEGENERATION

  • Researchers published in Bioactive Materials (October 2026) describe a strategy called NOX4-associated ferro-aging reprogramming, which uses an iron-chelating senescent-cell-targeted therapy to address oxidative stress and cellular senescence in aging intervertebral discs, potentially reversing a key driver of back pain and disability in older adults.
  • The approach specifically targets ferroptosis - an iron-dependent form of cell death - in senescent disc cells, combining senolytics (agents that clear old cells) with iron chelation in a single nanocomposite platform.

PSILOCYBIN AND COGNITIVE AGING - CLINICAL INVESTIGATION

  • A trial registered on ClinicalTrials.gov (NCT07721467) is investigating whether psilocybin can enhance neuroplasticity in older adults undergoing cognitive training, targeting normal aging and Alzheimer disease-related brain changes; the study is listed as of October 2026.
  • The premise is that psilocybin may amplify the brain's responsiveness to training by promoting synaptic plasticity via serotonin-2A receptor activation, potentially offering a pharmacological boost to non-drug cognitive interventions.

mTORC1 INHIBITION FOR DISC AGING

  • A study in Bioactive Materials (October 2026) from a Japanese team (Hiranaka, Yurube et al.) used cationized gelatin nanospheres loaded with siRNA targeting mTORC1 - a central regulator of cellular aging and autophagy - to protect intervertebral disc cells from degeneration, achieving controlled RNA interference release into aging disc tissue.
  • Inhibiting mTORC1 is one of the most studied geroscience strategies, as this pathway governs cell growth, autophagy, and senescence across species.

BONE REGENERATION IN AGING - SINGLE-CELL GUIDED DESIGN

  • Researchers in Biomaterials (August 2026) used single-cell transcriptomics to map the aged bone microenvironment and designed a cascade-responsive hydrogel with a bioinspired nanocellular pacemaker to drive bone repair specifically in elderly tissue, where standard regenerative approaches often fail due to impaired stem cell function.

AI FACE-BASED BIOLOGICAL AGE ESTIMATION

  • A study in Lancet Digital Health (publication date listed as June 2027, appearing in preprint/early access) by Haugg, Lee, Gladyshev, Aerts, Mak et al. describes FAHR-Face (Foundation AI models for Health Recognition using Face photographs), a deep-learning model validated to estimate biological age and health status from facial photographs, with senior author Vadim Gladyshev - a prominent aging biology researcher at Harvard.
  • Biological age clocks derived from non-invasive inputs like photographs could democratize longevity monitoring if validated, though clinical utility remains to be proven in prospective trials.

OSTEOARTHRITIS - NANOZYME HYDROGEL FOR CARTILAGE REPAIR

  • A team publishing in Bioactive Materials (October 2026) developed a DNA-adsorbing nanozyme hydrogel that reprograms the immune-oxidative microenvironment of arthritic joints to support stem cell-based cartilage repair, targeting the inflammatory milieu that accelerates age-related cartilage breakdown.

💊 NEW CURES & APPROVALS

NOTE: openFDA action dates are listed as invalid in the source data; the following approvals reflect supplemental or original actions recorded in Drugs@FDA without confirmed exact dates.

AYVAKIT (AVAPRITINIB) - BLUEPRINT MEDICINES

  • Blueprint Medicines received a supplemental approval (SUPPL AP) for Ayvakit, whose active ingredient is avapritinib, a KIT/PDGFRA kinase inhibitor used in gastrointestinal stromal tumors and systemic mastocytosis.

JEMPERLI (DOSTARLIMAB-GXLY) - GLAXOSMITHKLINE

  • GlaxoSmithKline received a supplemental approval for Jemperli, whose active ingredient is dostarlimab-gxly, a PD-1 checkpoint inhibitor used in endometrial cancer and mismatch repair-deficient solid tumors.

ORLADEYO (BEROTRALSTAT) - BIOCRYST

  • BioCryst received a supplemental approval for Orladeyo, active ingredient berotralstat dihydrochloride, a plasma kallikrein inhibitor indicated for prophylaxis of hereditary angioedema attacks in adults and pediatric patients aged 12 and older.

DAYBUE STIX (TROFINETIDE) - ACADIA PHARMACEUTICALS

  • ACADIA Pharmaceuticals received a supplemental approval for Daybue Stix, active ingredient trofinetide, a synthetic analog of the amino-terminal tripeptide of IGF-1 indicated for Rett syndrome, a severe neurological disorder primarily affecting girls.

PHYRAGO (DASATINIB) - HANDA THERAPEUTICS

  • Handa Therapeutics received a supplemental approval for Phyrago, active ingredient dasatinib, a BCR-ABL and Src-family kinase inhibitor used in chronic myeloid leukemia and acute lymphoblastic leukemia; dasatinib is also under active investigation as a senolytic agent in aging research.

IMKELDI (IMATINIB MESYLATE) - SHORLA ONCOLOGY

  • Shorla Oncology received a supplemental approval for Imkeldi, active ingredient imatinib mesylate, a tyrosine kinase inhibitor used across multiple oncologic indications including CML and gastrointestinal stromal tumors.

CABOZANTINIB S-MALATE - CIPLA (GENERIC)

  • Cipla received an original ANDA approval for a generic cabozantinib s-malate formulation, a multi-kinase inhibitor (targeting MET, VEGFR, RET, and AXL) used in renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.

🧪 CLINICAL TRIALS

PDE4 IMAGING IN ALZHEIMER DISEASE AND MCI

  • A ClinicalTrials.gov study (NCT07169630) is using PET imaging to quantify phosphodiesterase-4 (PDE4) - an enzyme linked to neuroinflammation and cognitive function - in volunteers with Alzheimer disease or mild cognitive impairment, with approximately 5 million U.S. adults estimated to have age-related brain disorders.
  • PDE4 inhibition is a mechanistic target for anti-inflammatory and pro-cognitive drug development; imaging the enzyme in living brains could accelerate target engagement studies for new treatments.

PSILOCYBIN FOR NEUROPLASTICITY IN OLDER ADULTS

  • Trial NCT07721467 on ClinicalTrials.gov is studying whether psilocybin combined with cognitive training can enhance brain neuroplasticity in older adults, addressing both normal aging and Alzheimer-related decline; listed as registering October 2026.

MEDITERRANEAN KETOGENIC NUTRITION ADHERENCE IN OLDER ADULTS

  • Trial NCT04817176 (ClinicalTrials.gov) is testing a 6-week telehealth Mediterranean ketogenic nutrition adherence program using motivational interviewing and cognitive behavioral therapy (MI-CBT) in older adults, with Mediterranean and ketogenic dietary patterns both linked to metabolic and cognitive aging benefits.

LONGITUDINAL NATURAL HISTORY OF PRKN- AND PINK1-LINKED PARKINSON DISEASE

  • Trial NCT07613112 is conducting a natural history study of PRKN and PINK1 gene-linked early-onset Parkinson disease, tracking disease progression to inform future intervention trials targeting the mitochondrial pathway these genes regulate.

SARCOPENIA IN ACUTE ISCHEMIC STROKE

  • An observational study (NCT07764172) is characterizing the prevalence and trajectory of sarcopenia - age-related muscle loss - in patients aged 50 and older with acute ischemic stroke, recognizing that muscle wasting accelerates post-stroke disability in older patients.

TELEMONITORING ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH COGNITIVE DEFICITS

  • A Canadian trial (NCT06888713) is evaluating remote monitoring of daily living activities in home care users aged 65 and older with cognitive deficits in Quebec, where more than 46,000 people were on wait lists for home care services.

AI-ASSISTED PREDICTION OF POSTOPERATIVE DELIRIUM

  • Trial NCT06216483 is a pilot RCT testing whether an AI-derived electronic medical record indicator of delirium risk can reduce postoperative delirium incidence and long-term cognitive decline in older surgical patients.

INPATIENT HOSPICE TRANSITIONS FOR DEMENTIA PATIENTS

  • An NIH Stage IB feasibility study (NCT07889830) is adapting and testing the Inpatient Hospice Transitions Checklist (I-HTC), an Epic-embedded tool supporting hospice eligibility assessment and communication for hospitalized persons living with dementia, registered October 22, 2026.

📢 PUBLIC HEALTH

U.S. WITHDRAWAL FROM WHO - COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on 22 January 2026, citing COVID-19 failures, politicization, and a shift to bilateral health diplomacy.
  • WHO stated the withdrawal makes both the United States and the world less safe; the U.S. exit was first notified on 24 January 2026 and considered by the WHO Executive Board on 2 February 2026.

CDC IMMUNIZATION SCHEDULE UPDATES

  • CDC updated its adult and child immunization schedules in October 2025 to apply individual-based decision-making for COVID-19 vaccination, and introduced standalone varicella vaccination as an option for toddlers.
  • ACIP voted in December 2025 to recommend individual-based decision-making for hepatitis B vaccine for infants born to mothers who test negative for hepatitis B virus, departing from the previous universal birth-dose recommendation.

RABIES ACTIVITY INCREASING

  • CDC issued a statement in September 2026 on increases in animal rabies activity and associated human exposures across the United States, urging public awareness about post-exposure prophylaxis.

CANCER MORTALITY DECLINING

  • The 2026 Annual Report to the Nation found that progress against lung cancer is driving down overall U.S. cancer mortality, attributed in part to reduced smoking rates and advances in targeted therapy and immunotherapy.

DRUG OVERDOSE DEATHS DECLINING

  • CDC's National Vital Statistics System data (May 2025) showed a 27 percent decrease in drug overdose deaths, a significant public health milestone after years of record highs.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

BIOMED PULSE | Sources: CDC Newsroom, WHO Disease Outbreak News, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261023-02-v114 · 2026-10-23 02:01 UTC · pulse.uzylab.com